Abstract: A suite of efficient authentication and key establishment protocols for securing contact or contactless interfaces between communicating systems. The protocols may be used in secure physical access, logical access and/or transportation applications, among other implementations. The system authenticates a mobile device such as a smart card and/or mobile phone equipped with a secure element presented to one or more host terminals and establishes shared secure messaging keys to protect communications between the device and terminal. Secure messaging provides an end-to-end protected path of digital documents or transactions through the interface. The protocols provide that the device does not reveal identification information to entities different from a trusted host.

Abstract: Inhibitors of HCV replication of formula (I) wherein W is a heterocycle of formula and the remaining variables are as defined in the specification.

Abstract: The present invention concerns the compounds having the formula N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites thereof, wherein R1 and R8 each are H, optionally substituted C1-6alkyl, C2-6alkenyl, C3-7cycloalkyl, aryl, Het1, Het2; R1 may also be a radical of formula (R11aR11b)NC(R10aR10b)CR9—; t is 0, 1 or 2; R2 is H or C1-6alkyl; L is —C(?O)—, —O—C(?O)—, —NR8—C(?O)—, —O—C1-6alkanediyl-C(?O)—, —NR8—C1-6alkanediyl-C(?O)—, —S(?O)2—, —O—S(?O)2—, —NR8—S(?O)2; R3 is C1-6alkyl, aryl, C3-7cycloalkyl, C3-7cycloalkylC1-4alkyl, or arylC1-4alkyl; R4 is H, C1-4alkylOC(?O), carboxyl, aminoC(?O), mono- or di(C1-4alkyl)aminoC(?O), C3-7cycloalkyl, C2-6alkenyl, C2-6alkynyl or optionally substituted C1-6alkyl; A is C1-6alkanediyl, —C(?O)—, —C(?S)—, —S(?O)2—, C1-6alkanediyl-C(?O)—, C1-6alkanediyl-C(?S)— or C1-6alkanediyl-S(?O)2—; R5 is H, OH, C1-6alkyl, Het1C1-6alkyl, Het2C1-6alkyl, optionally substituted amino-C1-6alkyl; R6 is C1-6alkylO, Het1, Het1O, Het2, Het2O, aryl, arylO, C1-

Abstract: This invention provides for progressive processing of biometric samples to facilitate verification of an authorized user. The initial processing is performed by a security token. Due to storage space and processing power limitations, excessive false rejections may occur. To overcome this shortfall, the biometric sample is routed to a stateless server, which has significantly greater processing power and data enhancement capabilities. The stateless server receives, processes and returns the biometric sample to the security token for another attempt at verification using the enhanced biometric sample. In a second embodiment of the invention, a second failure of the security token to verify the enhanced biometric sample sends either the enhanced or raw biometric sample to a stateful server. The stateful server again processes the biometric sample and performs a one to many search of a biometric database.

Abstract: The present invention concerns substituted aminophenylsulfonamide compounds, their use as protease inhibitors, in particular as broad-spectrum HIV protease inhibitors, processes for their preparation as well as pharmaceutical compositions and diagnostic kits comprising them. The present invention also concerns combinations of the present substituted aminophenylsulfonamide compounds with another anti-retroviral agent. It further relates to their use in assays as reference compounds or as reagents.

Abstract: An intelligent remote device equipped with a security token operatively coupled thereto is processing communications with a security token enabled computer system over a wireless private network. The intelligent remote device is adapted to emulate a local security device peripheral connected to the computer system. Multiple computer systems may be authenticated to using the intelligent remote device. Additionally, various secure communications connections mechanisms are described which are intended to augment existing security protocols available using wireless network equipment. Authentication of a user supplied critical security parameter is performed by the security token. The critical security parameter may be provided locally via the intelligent remote device or received from the wireless network and routed to the security token. Aural, visual or vibratory feedback may be provided to the user to signal a successful authentication transaction.

Abstract: Substituted fused bicyclic pyrimidine compounds having an amide-substituted pyridylamine group at C-4 of the pyrimidine ring are useful in the treatment of conditions associated with HCV.

Abstract: The present invention relates to the use of pyrido[2,3-d]pyrimidines of formula (I) wherein L, R1, R2 and R3 have specific meaning. The present invention also relates to the use of the compounds of formula (I) as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to compounds of formula (I) per se and their use as medicines. The present invention also concerns processes for the preparation of such compounds, pharmaceutical compositions comprising them, and combinations of said compounds with other anti-HCV agents.

Abstract: Inhibitors of HCV replication of formula (I) and the N-oxides, salts, and stereoisomers thereof, wherein each variable has specific definitions. Pharmaceutical compositions containing compounds (I) and process for preparing compounds (I) are also provided. Bioavailable combinations of the inhibitors of HCV of Formula (I) with ritonavir are also provided.

Abstract: Inhibitors of HCV of formula (I) and the N-oxides, salts, and stereochemically isomeric forms thereof, wherein the terms R1, L, R2, R3, R4, and n have specific definitions; pharmaceutical compositions containing compounds of formula (I), and processes for preparing compounds of formula (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.

Abstract: The present invention relates to the use of bi-cyclic pyrimidines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to processes for preparation of such pharmaceutical compositions. The present invention also concerns combinations of the present bi-cyclic pyrimidines with other anti-HCV agents.

Abstract: The present invention relates to a process for the preparation of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate as well as novel intermediates for use in said process. (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate is particularly useful as an HIV protease inhibitor.

Abstract: An intelligent remote device equipped with a security token operatively coupled thereto is processing communications with a security token enabled computer system over a wireless private network. The intelligent remote device is adapted to emulate a local security device peripheral connected to the computer system. Multiple computer systems may be authenticated to using the intelligent remote device. Additionally, various secure communications connections mechanisms are described which are intended to augment existing security protocols available using wireless network equipment. Authentication of a user supplied critical security parameter is performed by the security token. The critical security parameter may be provided locally via the intelligent remote device or received from the wireless network and routed to the security token. Aural, visual or vibratory feedback may be provided to the user to signal a successful authentication transaction.

Abstract: The present invention concerns the compounds having the formula N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites thereof, wherein R1 and R8 each are H, optionally substituted C1-6alkyl, C2-6alkenyl, C3-7cycloalkyl, aryl, Het1, Het2; R1 may also be a radical of formula (R11aR11b)NC(R10aR10b)CR9—; t is 0, 1 or 2; R2 is H or C1-6alkyl; L is —C(?O)—, —O—C(?O)—, —NR8—C(?O)—, —O—C1-6alkanediyl-C(?O)—, —NR8—C1-6alkanediyl-C(?O)—, —S(?O)2—, —O—S(?O)2—, —NR8—S(?O)2; R3 is C1-6alkyl, aryl, C3-7cycloalkyl, C3-7cycloalkylC1-4alkyl, or arylC1-4alkyl; R4 is H, C1-4alkylOC(?O), carboxyl, aminoC(?O), mono- or di(C1-4alkyl)aminoC(?O), C3-7cycloalkyl, C2-6alkenyl, C2-6alkynyl or optionally substituted C1-6alkyl; R5 and R6 are H or C1-6alkyl. It further relates to their use as broadspectrum HIV protease inhibitors, processes for their preparation as well as pharmaceutical compositions and diagnostic kits comprising them.

Abstract: The present invention concerns substituted aminophenylsulfonamide compounds and derivatives, their use as protease inhibitors, in particular as broadspectrum HIV protease inhibitors, processes for their preparation as well as pharmaceutical compositions and diagnostic kits comprising them. The present invention also concerns combinations of the present substituted aminophenylsulfonamide compounds and derivatives with another anti-retroviral agent. It further relates to their use in assays as reference compounds or as reagents.

Abstract: Inhibitors of HCV of formula al and the N-oxides, salts, and stereochemically isomeric forms thereof, wherein R1 is aryl or a saturated, a partially unsaturated or completely unsaturated 5 or 6 membered monocyclic or 8 to 12 membered bicyclic heterocyclic ring system containing one nitrogen, and optionally one to three oxygen, sulfur or nitrogen, wherein said ring system may be optionally substituted; L is a direct bond, —O—, —O—C1-4alkanediyl-, —O—CO—, —O—C(?O)—NR5a— or —O—C(?O)—NR5a—C1-4alkanediyl-; R2 is hydrogen, —OR6, —C(?O)OR6, —C(?O)R7, —C(?O)NR5aR5b, —C(?O)NHR5c, —NR5aR5b, —NHR5c, —NHSOpNR5aR5b, —NR5aSOpR8, or —B(OR6)2; R3 and R4 are hydrogen or C1-6alkyl; or R3 and R4 taken together may form a C3-7cycloalkyl ring; n is 3, 4, 5, or 6; p is 1 or 2; aryl is phenyl, naphthyl, indanyl, or 1,2,3,4-tetrahydronaphthyl, each of which may be optionally substituted Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroatoms each indepe

Abstract: A system is used for authorizing access to a Personal Security Device. This system comprises a Personal Security Device 75 and another device 105 which is in functional communication with said Personal Security Device. Said Personal Security Device comprises identification information retrieval data and a biometric authentication application 200 which transfers said identification information retrieval data to said other device 105 in response to an identified match between biometric data sent by said other device and a predetermined biometric reference. Said other device 105 comprises a security executive application 230 for retrieving an Identification Information with at least said identification information retrieval data, thus generating a retrieved Identification Information, and transferring said retrieved Identification Information to said Personal Security Device 75.

Abstract: The present invention relates to 5H-pyrazolo[1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as inhibitors of the viral replication of the HIV virus, processes for their preparation as well as pharmaceutical compositions, their use as medicines, and diagnostic kits comprising them. The present invention also concerns combinations of the present HIV inhibitors with other anti-retroviral agents. It further relates to their use in assays as reference compounds or as reagents. The compounds of the present invention are useful for preventing or treating infection by HIV and for treating AIDS.

Abstract: This invention provides for progressive processing of biometric samples to facilitate verification of an authorized user. The initial processing is performed by a security token. Due to storage space and processing power limitations, excessive false rejections may occur. To overcome this shortfall, the biometric sample is routed to a stateless server, which has significantly greater processing power and data enhancement capabilities. The stateless server receives, processes and returns the biometric sample to the security token for another attempt at verification using the enhanced biometric sample. In a second embodiment of the invention, a second failure of the security token to verify the enhanced biometric sample sends either the enhanced or raw biometric sample to a stateful server. The stateful server again processes the biometric sample and performs a one to many search of a biometric database.

Abstract: A suite of efficient authentication and key establishment protocols for securing contact or contactless interfaces between communicating systems. The protocols may be used in secure physical access, logical access and/or transportation applications, among other implementations. The system authenticates a mobile device such as a smart card and/or mobile phone equipped with a secure element presented to one or more host terminals and establishes shared secure messaging keys to protect communications between the device and terminal. Secure messaging provides an end-to-end protected path of digital documents or transactions through the interface. The protocols provide that the device does not reveal identification information to entities different from a trusted host.